Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Interleukin-2 × Clear all

NCT02169609 2024-04-22

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Phase 2 Completed

Neuroblastoma, Neoplasm, Residual